# PUBLIC SUMMARY DOCUMENT

**Product:** Dansac NovaLife 2 Flat GX+ Wafer

**Applicant:** Dansac

**Date of SPAP Meeting:** 12 October 2021

## Proposed Deletion on the Stoma Appliance Scheme

The applicant, Dansac, sought the deletion of two variants of Dansac NovaLife 2 Flat GX+ Wafer (SAS Code 80049D) in subgroup 4(b) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the two variants being discontinued. The products, including seven variants, are currently listed at a unit price of $4.742, with a maximum monthly quantity of 20 units.

## Substitute products

Not Applicable.

**Variants to be deleted**

| **Product Code** | **Description** |
| --- | --- |
| 1836-10 | no belt loops, mechanical coupling, 36mm ring, floating flange, 1.1mm, hydrocolloid baseplate, hydrocolloid self-adhesive, extended wear, oval, cut-to-fit, 10mm, release tabs, 28mm, |
| 1855-35 | no belt loops, mechanical coupling, 55mm ring, floating flange, 1.1mm, hydrocolloid baseplate, hydrocolloid self-adhesive, extended wear, oval, pre-cut, 35mm, release tabs, |

## Background

This product was first listed on the Scheme Schedule on 1 April 2016.

## Clinical Place for the Product

The proposed substitute products provide an alternative for users requiring a two-piece baseplate pouch with extended wear mechanical coupling.

### Financial Analysis

It is therefore, unlikely that there would be a budgetary impact for the Scheme as a consequence of deleting the two variants.

## Panel Recommendation

The Panel recommended the deletion of two variants of Dansac NovaLife 2 Flat GX+ Wafer (SAS Code 80049D) in subgroup 4(b) of the Scheme Schedule at the unit price of $4.742, with a maximum monthly quantity of 20 units.

The Panel also noted that Dansac is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletions. A period of approximately six months from the date of the Panel’s recommendation (12 October 2021) should be given to allow users of the variants to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

## Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.  
A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government.  
All Panel recommendations are subject to Cabinet/Ministerial approval.

## Applicant’s Comment

Dansac agrees with the SPAP recommendation.